The Pharmaceutical Suppression: Why a Safe, Effective Therapy Was Marginalized (Methylene Blue For Cellular Repair, Ch. 1 item 3) (2026)

Other · BrightLearn.ai (AI-generated book, no named author; footer: 'This book was created at BrightLearn.ai') · August 1, 2026

BrightLearn.ai (AI-generated book et al., 2026-08-01: Chapter of a BrightLearn.ai book stating that methylene blue was 'quietly pushed aside, ignored, and even ridiculed' because it 'cannot be patented in its natural form' and so threatens the pharmaceutical business model.

Now imagine that this same medicine was quietly pushed aside, ignored, and even ridiculed by the very institutions that should celebrate it.

BrightLearn.ai (AI-generated book et al., 2026-08-01: Chapter of a BrightLearn.ai book stating that methylene blue was 'quietly pushed aside, ignored, and even ridiculed' because it 'cannot be patented in its natural form' and so threatens the pharmaceutical business model. C5 BrightLearn suppression chapter; page carries schema datePublished 2026-08-01. text_file=C5_3.txt. Same chapter: 'Methylene blue costs pennies to produce. It cannot be patented in its natural form.' Sources it lists at chapter end: Sloan, The Ultimate Guide to Methylene Blue; Robert G. Wright, Killing Cancer Not People; Nina L. Etkin, Edible Medicines; a NaturalNews article (4 June 2025); a Mercola.com article (16 July 2023). None of those cited works is a primary document establishing suppression: SOURCE NOT FOUND. AI-generated text, treated as a published document of its publisher only. Study type: book.